Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies

[1]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[2]  G. Zadeh,et al.  High-Resolution In-Vivo Analysis of Normal Brain Response to Cranial Irradiation , 2012, PloS one.

[3]  M. Westphal,et al.  Glioblastoma Stem–like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration , 2012, Clinical Cancer Research.

[4]  C. Gondi,et al.  MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. , 2012, Cellular signalling.

[5]  Aaron S. Gajadhar,et al.  Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. , 2012, The Journal of clinical investigation.

[6]  A. Guha,et al.  Mouse Models to Interrogate the Implications of the Differentiation Status in the Ontogeny of Gliomas , 2011, Oncotarget.

[7]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[8]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[9]  Aaron S. Gajadhar,et al.  A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas , 2011, The Journal of experimental medicine.

[10]  P. Liberski,et al.  Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions , 2011, British Journal of Cancer.

[11]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[12]  Rong Wang,et al.  Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.

[13]  L. Kaufman,et al.  Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. , 2010, Cancer letters.

[14]  Thomas Benner,et al.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[16]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[17]  S. Kesari,et al.  Glioma stem cell signaling: therapeutic opportunities and challenges , 2010, Expert review of anticancer therapy.

[18]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Y. Marie,et al.  A New Alternative Mechanism in Glioblastoma Vascularization: Tubular Vasculogenic Mimicry , 2022 .

[20]  H. Vogel,et al.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.

[21]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[22]  Anssi Auvinen,et al.  Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974-2003. , 2009, Journal of the National Cancer Institute.

[23]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[24]  Erwin G. Van Meir,et al.  Brain cancer propagating cells: biology, genetics and targeted therapies. , 2009, Trends in molecular medicine.

[25]  C. James,et al.  Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. , 2009, International journal of radiation oncology, biology, physics.

[26]  Deric M. Park,et al.  Biology of glioma cancer stem cells , 2009, Molecules and cells.

[27]  X. Bian,et al.  Incorporation of endothelial progenitor cells into the neovasculature of malignant glioma xenograft , 2009, Journal of Neuro-Oncology.

[28]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[29]  Zhon-Yin Zhang.  Faculty Opinions recommendation of Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. , 2009 .

[30]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[31]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[32]  G. Ahn,et al.  Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature , 2009, Angiogenesis.

[33]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Parada,et al.  Inducible site‐specific recombination in neural stem/progenitor cells , 2009, Genesis.

[35]  Kurt Engeland,et al.  RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53 , 2008, Cell cycle.

[36]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[37]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[38]  M. Sánchez-Martín.  Brain tumour stem cells: implications for cancer therapy and regenerative medicine. , 2008, Current stem cell research & therapy.

[39]  V. Shoshan-Barmatz,et al.  Methyl jasmonate binds to and detaches mitochondria-bound hexokinase , 2008, Oncogene.

[40]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[41]  R. Weinberg,et al.  Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression , 2008, Cell.

[42]  D. Rowitch,et al.  Glioma Stem Cells: A Midterm Exam , 2008, Neuron.

[43]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[44]  P. Dirks,et al.  Brain tumor stem cells: bringing order to the chaos of brain cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Baker,et al.  Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells , 2008, Transgenic Research.

[46]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[47]  I. Sancho-Martinez,et al.  Yes and PI3K bind CD95 to signal invasion of glioblastoma. , 2008, Cancer cell.

[48]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[49]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[50]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[51]  S. Plotkin,et al.  Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. , 2007, Neurologic clinics.

[52]  Arjan W. Griffioen,et al.  Tumour vascularization: sprouting angiogenesis and beyond , 2007, Cancer and Metastasis Reviews.

[53]  R. Jain,et al.  Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors. , 2007, Cancer research.

[54]  K. McCarthy,et al.  Characterization of astrocyte‐specific conditional knockouts , 2007, Genesis.

[55]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[56]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[57]  M. Berens,et al.  Molecular targets of glioma invasion , 2007, Cellular and Molecular Life Sciences.

[58]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[59]  R. Jain,et al.  Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. , 2006, Seminars in oncology.

[60]  Saroj P. Mathupala,et al.  Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.

[61]  R. Henkelman,et al.  High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. , 2006, Cancer research.

[62]  C. James,et al.  Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response , 2006, Clinical Cancer Research.

[63]  A. Kyritsis,et al.  Mechanisms of angiogenesis in gliomas , 2006, Journal of Neuro-Oncology.

[64]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[65]  E. Chiocca,et al.  Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[67]  K. Ligon,et al.  Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma , 2005, Journal of neuropathology and experimental neurology.

[68]  D. Louis,et al.  In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. , 2005, The American journal of pathology.

[69]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[70]  Dawen Zhao,et al.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. , 2005, Cancer cell.

[71]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[72]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[73]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[74]  C. Thompson,et al.  Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. , 2004, Molecular cell.

[75]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[76]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[77]  D. Ribatti.  The involvement of endothelial progenitor cells in tumor angiogenesis , 2004, Journal of cellular and molecular medicine.

[78]  Daniel J Brat,et al.  Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. , 2004, The international journal of biochemistry & cell biology.

[79]  E. Voest.  Angiogenesis: from understanding to targeting. , 2004, Biochimica et biophysica acta.

[80]  T. Yanagida,et al.  Engagement of CD44 Promotes Rac Activation and CD44 Cleavage during Tumor Cell Migration* , 2004, Journal of Biological Chemistry.

[81]  K. Aldape,et al.  Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR , 2004, Genes, chromosomes & cancer.

[82]  Philip Hahnfeldt,et al.  Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. , 2003, Cancer research.

[83]  W. Kao,et al.  Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  A Vacca,et al.  New non-angiogenesis dependent pathways for tumour growth. , 2003, European journal of cancer.

[85]  P. Muehlbauer.  Anti-angiogenesis in cancer therapy. , 2003, Seminars in oncology nursing.

[86]  H. Choy,et al.  Chemotherapy and irradiation interaction. , 2003, Seminars in oncology.

[87]  Gerald McMahon,et al.  SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.

[88]  J. Debus,et al.  SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. , 2003, Cancer research.

[89]  J. S. Rao,et al.  Molecular mechanisms of glioma invasiveness: the role of proteases , 2003, Nature Reviews Cancer.

[90]  William A Weiss,et al.  Genetic determinants of malignancy in a mouse model for oligodendroglioma. , 2003, Cancer research.

[91]  S. Kiselev,et al.  Molecular Mechanisms of Tumor Angiogenesis , 2003, Biochemistry (Moscow).

[92]  D. Gutmann,et al.  Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. , 2003, Cancer research.

[93]  R. Weichselbaum,et al.  Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. , 2003, Cancer research.

[94]  L. Ellis,et al.  Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice , 2002, International journal of cancer.

[95]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[96]  G. Fuller,et al.  Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. , 2002, Cancer research.

[97]  Saroj P. Mathupala,et al.  Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. , 2002, Biochimica et biophysica acta.

[98]  Dana M. King,et al.  Loss of neurofibromatosis-1 and p19ARF cooperate to induce a multiple tumor phenotype , 2002, Oncogene.

[99]  R. Stern,et al.  Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. , 2002, Experimental cell research.

[100]  I. Herman,et al.  Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.

[101]  P. Pandolfi,et al.  Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. , 2002, Cancer cell.

[102]  C. Thompson,et al.  Cell metabolism in the regulation of programmed cell death , 2002, Trends in Endocrinology & Metabolism.

[103]  J. Hoek,et al.  Mitochondrial Binding of Hexokinase II Inhibits Bax-induced Cytochrome c Release and Apoptosis* , 2002, The Journal of Biological Chemistry.

[104]  R. K. Jain,et al.  Vessels of death or life. , 2001, Scientific American.

[105]  T. Ichinohe.  Tumor Angiogenesis and Microcirculation , 2001, International journal of hematology.

[106]  David E. Misek,et al.  Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. , 2001, Cancer research.

[107]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[108]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[109]  P. Black,et al.  αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .

[110]  Shin Jung,et al.  Hyaluronate Receptors Mediating Glioma Cell Migration and Proliferation , 2001, Journal of Neuro-Oncology.

[111]  P. Dirks.  Glioma Migration: Clues from the Biology of Neural Progenitor Cells and Embryonic CNS Cell Migration , 2001, Journal of Neuro-Oncology.

[112]  D. Gutmann,et al.  Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. , 2001, Cancer research.

[113]  E. Voest,et al.  Tumor Angiogenesis and Microcirculation , 2001 .

[114]  D. Hallahan,et al.  Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. , 2001, Cancer research.

[115]  Eric C. Holland,et al.  Gliomagenesis: genetic alterations and mouse models , 2001, Nature Reviews Genetics.

[116]  Sybill Patan,et al.  Vasculogenesis and Angiogenesis as Mechanisms of Vascular Network Formation, Growth and Remodeling , 2000, Journal of Neuro-Oncology.

[117]  V. Puduvalli,et al.  Antiangiogenesis – Therapeutic Strategies and Clinical Implications for Brain Tumors , 2000, Journal of Neuro-Oncology.

[118]  Gerhard Christofori,et al.  Molecular Mechanisms of Tumor Angiogenesis and Tumor Progression , 2000, Journal of Neuro-Oncology.

[119]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[120]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[121]  Karlyne M. Reilly,et al.  Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects , 2000, Nature Genetics.

[122]  B. Engelward,et al.  In vivo repair of methylation damage in Aag 3-methyladenine DNA glycosylase null mouse cells. , 2000, Nucleic acids research.

[123]  Eric C. Holland,et al.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.

[124]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[125]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[126]  Brem.  Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. , 1999, Cancer control : journal of the Moffitt Cancer Center.

[127]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[128]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[129]  M. Berens,et al.  "...those left behind." Biology and oncology of invasive glioma cells. , 1999, Neoplasia.

[130]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[131]  R. Johnston,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1998.0291 , 2022 .

[132]  C. Ackerley,et al.  Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression. , 1999, Journal of neuropathology and experimental neurology.

[133]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[134]  M. Nistér,et al.  Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. , 1998, Cancer research.

[135]  D. Cooper,et al.  Alkylpurine–DNA–N-Glycosylase Knockout Mice Show Increased Susceptibility to Induction of Mutations by Methyl Methanesulfonate , 1998, Molecular and Cellular Biology.

[136]  A. Aguzzi,et al.  Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice , 1997, Oncogene.

[137]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[138]  M. Westphal,et al.  Glioma invasion in the central nervous system. , 1996, Neurosurgery.

[139]  B. Christ,et al.  Embryonic angiogenesis: A review , 1996, Naturwissenschaften.

[140]  R. Tamargo,et al.  Inhibition of Tumor Angiogenesis a , 1994, Annals of the New York Academy of Sciences.

[141]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[142]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[143]  F. Dieterlen‐Lièvre,et al.  Vasculogenesis in the early quail blastodisc as studied with a monoclonal antibody recognizing endothelial cells. , 1987, Development.

[144]  P. Pedersen,et al.  High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[145]  P. Bailey,et al.  A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis , 1970 .

[146]  W. Dandy,et al.  REMOVAL OF RIGHT CEREBRAL HEMISPHERE FOR CERTAIN TUMORS WITH HEMIPLEGIA: PRELIMINARY REPORT , 1928 .

[147]  J. Globus,et al.  SPONGIOBLASTOMA MULTIFORME: A PRIMARY MALIGNANT FORM OF BRAIN NEOPLASM: ITS CLINICAL AND ANATOMIC FEATURES , 1925 .

[148]  J. Golfinos,et al.  Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. , 2012, International journal of radiation oncology, biology, physics.

[149]  L. Ricci-Vitiani,et al.  Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.

[150]  H. Armah.  Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model , 2010 .

[151]  Miriam Scadeng,et al.  Development of a novel mouse glioma model using lentiviral vectors , 2009, Nature Medicine.

[152]  R. Kiss,et al.  Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. , 2009, Advances and technical standards in neurosurgery.

[153]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[154]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[155]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[156]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[157]  P. Black,et al.  Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. , 2001, Neurosurgery.

[158]  R. Jain,et al.  Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. , 2001, Cancer research.

[159]  E. Bettelli,et al.  Arch.Immunol.Ther.Exp. , 2000 .

[160]  H. Kurz,et al.  Development of the embryonic vascular system. , 1995, Cellular & molecular biology research.

[161]  P. Vaupel,et al.  Therapeutic angiogenesis. , 1993, Archives of surgery.

[162]  W. Risau.  Embryonic angiogenesis factors. , 1991, Pharmacology & therapeutics.

[163]  R. Virchow,et al.  Die krankhaften Geschwülste , 1978 .

[164]  S. Weinhouse.  On respiratory impairment in cancer cells. , 1956, Science.

[165]  G. Fleming.  Spongioblastoma Multiforme. (Arch. of Neur. and Psychiat., August, 1925.) Globus, J. H., and Strauss, I. , 1926 .